Novaliq and BLP Management Group have formed Betaliq, a company that will develop beta-blockers for the treatment of glaucoma, according to a press release.
Betaliq, based in Tampa, Florida, has two preservative-free glaucoma drug candidates in its pipeline that both use Novaliq’s EyeSol water-free technology.
“With Betaliq, we aim to transform how glaucoma patients can be treated in the future, expanding application of EyeSol to another major indication,” Christian Roesky, Novaliq’s CEO and member of the Betaliq board of directors, said in the release. “Our latest
Uncategorized